Updated: Mar 24
This article is brought to you by the new Higher Learning LV Core Cannabis course.
Welcome to homework assignment 1.13 of the Core Cannabis Training Track from Higher Learning LV. When you complete this assignment, simply click the link at the bottom of the article to return to the master page for this training track.
Welcome to Cannabinoid Clinic, an education project powered by Higher Learning LV. This series provides cannabis and hemp industry professionals with easily digested cannabinoid profiles that ask little of your time—but provide plenty of science-based information.
There are two categories of cannabinoids: Phytocannabinoids and endocannabinoids. Phytocannabinoids are those produced by cannabis/marijuana/hemp, while endocannabinoids are made by the human body. This series covers both.
CBG molecular structure
What is CBG?
Cannabigerol (CBG) is the result of CBGA, the acidic precursor for this pivotal cannabinoid. It is considered a minor cannabinoid because it is typically available in relatively low volumes compared to major cannabinoids such as cannabidiol (CBD) and tetrahydrocannabiol (THC) (under one percent).
Non-psychoactive, CBG may help patients suffering from a range of conditions, including glaucoma, cancer, and Huntington's disease.
Although not psychoactive, anecdotal testimonies and scientific research has revealed that CBG may help patients suffering from a range of conditions, including glaucoma, cancer, and Huntington's disease.
First isolated in 1964 by Dr. Yehiel Gaoni and Dr. Raphael Mechoulam in Israel, CBG offers anti-inflammatory and antibacterial powers that may be of value in the treatment of a wide range of disease states and conditions.
To see the Fast Facts and Research Studies sections that have been removed from this no-cost training asset, enroll in Core Cannabis.
Return to the Core Cannabis Training Track master page.
Like what you just read? Check out our new Cannabis for Cancer Hub that features links to all of our articles about marijuana for cancer.